115 related articles for article (PubMed ID: 38746989)
1. Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT-7117), an Oral Melanocortin-1 Receptor Agonist.
Ogasawara A; Ide R; Inoue S; Teng R; Kawaguchi A
Clin Pharmacol Drug Dev; 2024 May; ():. PubMed ID: 38746989
[TBL] [Abstract][Full Text] [Related]
2. Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist.
Ogasawara A; Ogawa K; Ide R; Ikenaga Y; Fukunaga C; Nakayama S; Tsuda M
Eur J Clin Pharmacol; 2023 Jun; 79(6):801-813. PubMed ID: 37060458
[TBL] [Abstract][Full Text] [Related]
3. Absorption, metabolism, and excretion of [
Tsuda M; Ogawa K; Endou T; Goto T; Ogasawara Y; Ogasawara A
Pharmacol Res Perspect; 2023 Jun; 11(3):e01084. PubMed ID: 37078227
[TBL] [Abstract][Full Text] [Related]
4. The Oral Bioavailability and Effect of Various Gastric Conditions on the Pharmacokinetics of Dersimelagon in Healthy Adult Volunteers.
Ogawa K; Ide R; Belongie K; Tsuda M; Kawanishi H; Teng R; Ogasawara A
Clin Pharmacol Drug Dev; 2023 May; 12(5):493-501. PubMed ID: 36840969
[TBL] [Abstract][Full Text] [Related]
5. Dersimelagon in Erythropoietic Protoporphyrias.
Balwani M; Bonkovsky HL; Levy C; Anderson KE; Bissell DM; Parker C; Takahashi F; Desnick RJ; Belongie K;
N Engl J Med; 2023 Apr; 388(15):1376-1385. PubMed ID: 37043653
[TBL] [Abstract][Full Text] [Related]
6. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
8. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
9. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.
Mercier AK; Sunnåker M; Ueckert S; Pawlik T; Henricson E; Molodetskyi O; Law GC; Parker VER; Oscarsson J
Clin Pharmacokinet; 2023 Dec; 62(12):1713-1724. PubMed ID: 37801266
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Kaufmann P; Cruz HG; Krause A; Ulč I; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2016 Aug; 82(2):369-79. PubMed ID: 27062188
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
[TBL] [Abstract][Full Text] [Related]
14. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
[TBL] [Abstract][Full Text] [Related]
16. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
17. Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
Younis IR; Hsueh CH; Nelson C; Billin AN; Yue MS; Xiao D; Watkins TR; Othman AA
J Clin Pharmacol; 2023 Sep; 63(9):1017-1025. PubMed ID: 37128693
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
[TBL] [Abstract][Full Text] [Related]
19. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.
Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Chen W; Bello A; Murthy B
Clin Pharmacokinet; 2022 Jun; 61(6):857-867. PubMed ID: 35262846
[TBL] [Abstract][Full Text] [Related]
20. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
